PeptideStack
5.2kquestions
20kanswers
220users

What happens to dulaglutide after eight weeks at 25 °C in solution?

Asked 31 Mar 2025Modified 12 months agoViewed 15k times
21

What I am working with: dulaglutide · eight weeks · 25 °C.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

What is the causal chain, and where does it stop being established?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
LM
askedlucia_marchetti19k2731 Mar 2025

2 Answers

Sorted by votes
80

eight weeks is 56 days, which at 25 °C is on the order of 224 refrigerated days. 25 °C is 20 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 4 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. In solution the routes that matter are hydrolysis of the backbone, deamidation at Asn, and physical association — the first two cost content, the third costs neither until it precipitates. Over 56 days at 25 °C you should expect all three to have moved, and a purity figure to have noticed only some of them. Reconstituted material has no certificate; the one in the box describes the powder.

The part that matters: this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Concretely, deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

edited 26 Jul 2025 by day_seven_trough — updated for the 2026 guidance change

shareimprove this answerflag
DT
answeredday_seven_trough6.7k144 Jul 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
53

Concretely, aggregation is a physical process and is the one most often caused by handling rather than by time.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Stated carefully, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

edited 26 Jul 2025 by marta_okonkwo — tightened the wording; no substantive change

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25816 Jul 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.